Autonomous artificial intelligence (AI) in healthcare is paving the way to achieve new breakthroughs in care for patients and providers while improving long term care outcomes. Tarzana Treatment Centers (TTC), a full-service primary and behavioral healthcare organization with several locations throughout the greater Los Angeles area, recently identified a way to increase care access for their 33,000 patients with complex medical needs by adopting LumineticsCore™ (formerly IDx-DR), an AI diagnostic system that autonomously diagnoses patients for diabetic retinopathy (including macular edema).
TTC’s more than 1,200 patients diagnosed with diabetes have struggled with socioeconomic challenges and the ability to access an annual eye exam for diabetes, which is critical for identifying diabetic retinopathy (DR), an eye condition caused by complications related to diabetes. DR is a leading cause of blindness for people living with diabetes – but vision loss caused by DR is preventable with early detection, timely treatment, and appropriate follow-up care.
While TTC already leveraged remote reading networks as part of their eye care exam for testing for DR, they wanted to further increase their ability to meet the urgent medical needs of their at-risk patient population and identify debilitating eye disease early. By implementing the LumineticsCore autonomous AI system, TTC was able to drastically improve access to essential eye exams for these patients and significantly reduce time-to-follow-up with an eyecare specialist from months to a few days. The Reseda Primary Care Clinic, an early adopter of the autonomous AI within the TTC network, elevated completion of eye exams for diabetes from 25% using a reading network to 71% using LumineticsCore autonomous AI in the first nine months alone.
“When we have a patient with a positive diagnosis, the clinical team has a feeling of satisfaction. We know we will intervene with a referral to eyecare the same day, potentially saving their vision,” said Nicholas Hermann, PA-C.
TTC provides necessary care to some of Southern California’s most vulnerable patient populations, including those who are most at risk of lasting diabetes-related vision damage that is preventable with early intervention. They have achieved a new, more effective level of patient care with the adoption of LumineticsCore across all six of their care centers.
Read more details about how TTC increased their rates of EED, reduced time-to-follow-up, and improved patient outcomes.